Floatz logo

Tusamitamab Ravtansine

Neoplasm

Sanofiantibody_drug_conjugatePhase 1Active
D
23/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
8/ 100
Competitive Position
89/ 100

Competitive context

927 Active assets in the Neoplasm cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

Tusamitamab Ravtansine is also rated in:

non-small cell lung carcinomaDormant
D
Indicative ·
30 / 100
View asset →
lung cancerDormant
D
Indicative ·
29 / 100
View asset →
breast cancerDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →